85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-001276-27-GB
(EUCTR)
21/08/201703/05/2017A study to determine if GBT440 can increase the level of oxygen in the blood of people with Idiopathic Pulmonary Fibrosis (IPF) who need to use supplemental oxygen when resting.A Phase II open label study to evaluate the effect of GBT440 on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF) who are using supplemental oxygen at rest (ZEPHYR) - ZEPHYR Idiopathic Pulmonary Fibrosis (IPF)
MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: GBT440 300 mg capsule
Product Code: GBT440
Product Name: GBT440 300 mg tablet
Product Code: GBT440
Global Blood Therapeutics Inc.NULLNot Recruiting Female: yes
Male: yes
32 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;United Kingdom
2NCT02989168
(ClinicalTrials.gov)
November 201628/11/2016Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at RestA Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)Idiopathic Pulmonary Fibrosis;HypoxemiaDrug: GBT440Global Blood TherapeuticsNULLTerminated45 Years85 YearsAll14Phase 2United States;United Kingdom
3NCT02846324
(ClinicalTrials.gov)
June 20167/7/2016Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPFA Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis;HypoxemiaDrug: GBT440;Drug: PlaceboGlobal Blood TherapeuticsNULLCompleted45 Years80 YearsAll39Phase 2United States